Other
Igg4 Related Disease
0
Pipeline Programs↗
6
Active Trials↗
4
Companies Involved↗
IgG4 Related Disease is an early-stage landscape with 0 programs across 4 companies. The most active players are Principia Biopharma, a Sanofi Company, Zenas BioPharma (USA), LLC, Amgen.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
21
clinical trials
Unknown status7 · 33%
Completed7 · 33%
Recruiting3 · 14%
Not yet recruiting2 · 10%
Active, not recruiting1 · 5%
Available1 · 5%
Clinical Trials
Trial Activity
21 trials
An Exploratory Clinical Study on the Safety and Efficacy of CD19/BCMA CAR-NK in the Treatment of Relapsed and Refractory IgG4-related Disease
Not yet recruiting·—·Phase 1·NCT07298590·18 enrolled
Leflunomide for Maintenance of Remission in IgG4 Related Disease
Completed·—·Phase 4·NCT02703194·68 enrolled
Zanubrutinib in Patients With IgG4-Related Disease
Completed·—·Phase 2·NCT04602598·10 enrolled
To Evaluate the Clinical Efficacy of Iguratimod in the Treatment of IgG4 Related Disease (IgG4-RD) With Mild Symptom
Unknown status·—·Phase 4·NCT03368274·30 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)